AMRX vs. AMPH, DCPH, RCKT, NAMS, ARDX, GLPG, SNDX, KROS, EWTX, and AGIO
Should you be buying Amneal Pharmaceuticals stock or one of its competitors? The main competitors of Amneal Pharmaceuticals include Amphastar Pharmaceuticals (AMPH), Deciphera Pharmaceuticals (DCPH), Rocket Pharmaceuticals (RCKT), NewAmsterdam Pharma (NAMS), Ardelyx (ARDX), Galapagos (GLPG), Syndax Pharmaceuticals (SNDX), Keros Therapeutics (KROS), Edgewise Therapeutics (EWTX), and Agios Pharmaceuticals (AGIO). These companies are all part of the "pharmaceutical preparations" industry.
Amneal Pharmaceuticals (NASDAQ:AMRX) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation, dividends and community ranking.
Amneal Pharmaceuticals presently has a consensus price target of $8.25, suggesting a potential upside of 20.44%. Amphastar Pharmaceuticals has a consensus price target of $66.00, suggesting a potential upside of 59.81%. Given Amphastar Pharmaceuticals' higher possible upside, analysts plainly believe Amphastar Pharmaceuticals is more favorable than Amneal Pharmaceuticals.
Amphastar Pharmaceuticals has lower revenue, but higher earnings than Amneal Pharmaceuticals. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Amphastar Pharmaceuticals has a net margin of 22.88% compared to Amneal Pharmaceuticals' net margin of -6.76%. Amneal Pharmaceuticals' return on equity of 234.06% beat Amphastar Pharmaceuticals' return on equity.
Amneal Pharmaceuticals has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, Amphastar Pharmaceuticals has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500.
Amphastar Pharmaceuticals received 377 more outperform votes than Amneal Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Amneal Pharmaceuticals an outperform vote while only 66.78% of users gave Amphastar Pharmaceuticals an outperform vote.
31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 17.5% of Amneal Pharmaceuticals shares are owned by insiders. Comparatively, 27.1% of Amphastar Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Amphastar Pharmaceuticals had 12 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 20 mentions for Amphastar Pharmaceuticals and 8 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 1.02 beat Amphastar Pharmaceuticals' score of 0.91 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media.
Summary
Amphastar Pharmaceuticals beats Amneal Pharmaceuticals on 11 of the 18 factors compared between the two stocks.
Get Amneal Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Amneal Pharmaceuticals Competitors List
Related Companies and Tools
